Literature DB >> 14586066

Telomerase activity in well-differentiated papillary thyroid carcinoma correlates with advanced clinical stage of the disease.

Leticia Bornstein-Quevedo1, M L García-Hernández, Ignacio Camacho-Arroyo, Miguel F Herrera, Arturo Angeles Angeles, Ofelia González Treviño, Armando Gamboa-Domínguez.   

Abstract

Clinical relevance and stage correlation of telomerase activity in well-differentiated papillary thyroid carcinoma (WD PTC) has not been well determined, as its reported activity could be due to the analysis of tumors with lymphocytic infiltrates or aggressive variants of papillary carcinomas. We conducted a prospective study of telomerase activity in WD PTC without inflammatory infiltrates and correlated it with clinical stage. Fifty WD PTCs were analyzed for telomerase activity by PCR-based TRAP (telomeric repeat amplification protocol) assay. Results were correlated with stage and other clinicopathologic variables. Twenty-one (42%) WD PTCs demonstrated telomerase activity. The enzyme was detected more frequently in stage III/IVa WD PTCs (p = 0.02) and in tumors with extra thyroidal extension (p = 0.04). The risk of presenting advanced disease (stage III/IVa) and extrathyroidal growth was significantly increased in telomerase-positive tumors (p = 0.01; odds ratio [OR] 4.4 [95%CI 1.3-14.7]) and (p = 0.04; OR 3.6 [95%CI 1.1-11.7]), respectively. Also, a correlation was found between telomerase activity and age. There was no correlation of telomerase activity with gender, histologic variant, tumor size, or cervical lymph node metastasis. Telomerase activity was observed in 42% of WD PTC and was detected more frequently in AJCC TNM stage III/IVa cases. This finding suggests that telomerase deregulation could be involved in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586066     DOI: 10.1007/s12022-003-0013-3

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  23 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 2.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment.

Authors:  L E Sanders; B Cady
Journal:  Arch Surg       Date:  1998-04

4.  Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications.

Authors:  P Matthews; C J Jones; J Skinner; M Haughton; C de Micco; D Wynford-Thomas
Journal:  J Pathol       Date:  2001-06       Impact factor: 7.996

5.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

Authors:  T M Bryan; A Englezou; L Dalla-Pozza; M A Dunham; R R Reddel
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT.

Authors:  S L Weinrich; R Pruzan; L Ma; M Ouellette; V M Tesmer; S E Holt; A G Bodnar; S Lichtsteiner; N W Kim; J B Trager; R D Taylor; R Carlos; W H Andrews; W E Wright; J W Shay; C B Harley; G B Morin
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

7.  Telomerase activity in human thyroid carcinomas originating from the follicular cells.

Authors:  P Brousset; N Chaouche; F Leprat; F Branet-Brousset; H Trouette; R C Zenou; J P Merlio; G Delsol
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

8.  Telomerase activity in benign and malignant thyroid diseases.

Authors:  K Yashima; F Vuitch; A F Gazdar; T J Fahey
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

9.  Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.

Authors:  K C Loh; F S Greenspan; L Gee; T R Miller; P P Yeo
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

10.  Telomerase activity in benign and malignant human thyroid tissues.

Authors:  A J Cheng; J D Lin; T Chang; T C Wang
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  5 in total

1.  Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study.

Authors:  Sheng-Lan Wang; Wan-Tzu Chen; Ming-Tsang Wu; Hon-Man Chan; Sheau-Fang Yang; Chee-Yin Chai
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 2.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

3.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

4.  New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer.

Authors:  Andrzej J Lachinski; Tomasz Stefaniak; Jarek Kobiela; Saxon Connor; Zbigniew Gruca; Zbigniew Sledzinski
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

Review 5.  Telomeres and Cancer.

Authors:  Hueng-Chuen Fan; Fung-Wei Chang; Jeng-Dau Tsai; Kao-Min Lin; Chuan-Mu Chen; Shinn-Zong Lin; Ching-Ann Liu; Horng-Jyh Harn
Journal:  Life (Basel)       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.